<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157586</url>
  </required_header>
  <id_info>
    <org_study_id>DM/PR/7401/005/00</org_study_id>
    <nct_id>NCT00157586</nct_id>
  </id_info>
  <brief_title>Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)</brief_title>
  <official_title>A Multicenter, Randomized, Prospective, Double-blind Study to Evaluate the Nephroprotective Effect of Delapril Alone or Combined With Manidipine in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <brief_summary>
    <textblock>
      Diabetes mellitus is one of the most common diseases globally, and is considered epidemic in&#xD;
      many developed and newly industrialized nations. Diabetes mellitus represents the single&#xD;
      largest cause of end-stage renal disease in the U.S. and Europe. At the same time, the&#xD;
      primary cause of early death in diabetic patients are cardiovascular complications.&#xD;
      Experimental and clinical studies found that angiotensin converting enzyme inhibitors (ACEi)&#xD;
      and calcium channel blockers (CCBs) have a specific renoprotective effect and that this&#xD;
      effect can be magnified when the two drugs are used in combination. To formally test this&#xD;
      hypothesis we designed the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)&#xD;
      study, a prospective, randomized, double blind trial aimed to compare the effect of 3 years&#xD;
      treatment with the ACEi Delapril (30 mg/day), alone or combined to the CCB Manidipine (10&#xD;
      mg/day), versus conventional (non ACEi, non CCB) therapy on the rate of renal function loss&#xD;
      and on the incidence of major cardiovascular events in 342 normo- and micro-albuminuric&#xD;
      hypertensive type 2 diabetic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION Optimal blood pressure, glycemic and lipid control are of utmost importance to&#xD;
      minimize the incidence and the progression of chronic renal and cardiovascular complications&#xD;
      in patients with diabetes mellitus type 2. Whether angiotensin converting enzyme (ACE)&#xD;
      inhibitors alone or combined to calcium channel blockers (CCB) may further reduce the&#xD;
      incidence and progression of chronic complications is worth investigating.&#xD;
&#xD;
      AIMS The primary aim of this study is to assess whether at comparable levels of optimal blood&#xD;
      pressure and metabolic control, the ACE inhibitor delapril alone or in combination with the&#xD;
      dihydropyridine CCB manidipine slow the rate of glomerular filtration rate (GFR) decline as&#xD;
      compared with placebo plus conventional antihypertensive therapy in patients with diabetes&#xD;
      mellitus type 2 and hypertension. The secondary aim of this study is to assess the effects of&#xD;
      delapril and manidipine on the incidence of major cardiovascular events (acute myocardial&#xD;
      infarction, ictus or stroke, heart failure requiring hospitalization, revascularization,&#xD;
      amputation and cardiovascular mortality).&#xD;
&#xD;
      STUDY POPULATION 342 hypertensive type 2 diabetes patients with normo- or micro-albuminuria.&#xD;
      STUDY DESIGN This is a multicenter, prospective, randomized, double-blind, placebo-controlled&#xD;
      study. After a 12-week baseline period in which prohibited antihypertensive treatments (ACE&#xD;
      inhibitors, angiotensin II receptor antagonists or dihydropyridine calcium channel blockers)&#xD;
      will be discontinued, patients will be stratified according to their urinary albumin&#xD;
      excretion rate in normo- and micro-albuminuric and then randomized to delapril alone (30&#xD;
      mg/day), delapril (30 mg/day) combined with manidipine (10 mg/day) or placebo given once&#xD;
      daily in the morning for at least three years. During the study, systolic and diastolic blood&#xD;
      pressure in all treatments groups will be maintained ≤ 120 and 80 mmHg respectively, with&#xD;
      fixed doses of study treatments and flexible doses of permitted antihypertensive therapy&#xD;
      (diuretics, beta blockers, alfa blockers, centrally acting adrenergic blockers. Blood&#xD;
      pressure, blood glucose concentrations and urinary albumin excretion rate will be monitored&#xD;
      every three months. Serum lipid concentrations and GFR (estimated with the iohexol plasma&#xD;
      clearance) will be measured every six months.&#xD;
&#xD;
      Primary and Secondary Variables. The primary efficacy variable of this study is the rate of&#xD;
      GFR decline. The secondary efficacy variable will be the incidence of major cardiovascular&#xD;
      events (acute myocardial infarction, ictus or stroke, heart failure requiring&#xD;
      hospitalization, revascularization, amputation and cardiovascular mortality).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date>June 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of decline of glomerular filtration rate (GFR).GFR is measured at baseline,and at 6,12,18,24,30 and 36 months after randomization</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
  </secondary_outcome>
  <enrollment>342</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delapril, Delapril-Manidipine Fixed combination</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 40 years&#xD;
&#xD;
          -  History of diabetes mellitus type 2 for at least three months with stable antidiabetic&#xD;
             treatment&#xD;
&#xD;
          -  Systolic and/or diastolic blood pressure ≥ 135 or 85 mmHg, respectively. In&#xD;
             alternative, antihypertensive therapy regardless of blood pressure values&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Urinary albumin excretion rate &lt; 200 µg/min&#xD;
&#xD;
          -  Written informed consent for the trial participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical or histological evidence of non-diabetic renal disease, including vascular&#xD;
             disease of the kidney, obstructive uropathy, prostatic hypertrophy or incomplete&#xD;
             bladder emptying&#xD;
&#xD;
          -  Transplanted kidney&#xD;
&#xD;
          -  Moderate to severe chronic heart failure (III-IV stage according to the NYHA&#xD;
             classification).&#xD;
&#xD;
          -  Cerebral hemorrhage, stroke or transient ischemic attack within three months prior to&#xD;
             the trial enrolment&#xD;
&#xD;
          -  Myocardial infarction within three months prior to the trial enrolment&#xD;
&#xD;
          -  Unstable angina pectoris&#xD;
&#xD;
          -  Mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Secondary (e.g., Cushing disease, phaeochromocytoma, etc.) or severe refractory&#xD;
             hypertension&#xD;
&#xD;
          -  Poor glycemic control (HbA1c&gt;11%)&#xD;
&#xD;
          -  Connective tissue or autoimmune disease&#xD;
&#xD;
          -  Hereditary angioneurotic edema&#xD;
&#xD;
          -  Clinically relevant electrolyte imbalance (e.g., serum potassium &gt; 5.5 mmol/L)&#xD;
&#xD;
          -  Clinically relevant hematological disorders&#xD;
&#xD;
          -  Anemia with hemoglobin concentrations &lt; 10 g/dL&#xD;
&#xD;
          -  Serious hepatic disease&#xD;
&#xD;
          -  Pregnancy or lactating or planning a pregnancy&#xD;
&#xD;
          -  Women of childbearing potential without following a scientifically accepted form of&#xD;
             contraception&#xD;
&#xD;
          -  Any other serious or terminal concomitant disease&#xD;
&#xD;
          -  Any condition which may interfere with the absorption of the study treatments&#xD;
&#xD;
          -  Any concomitant treatment with ACE inhibitors, angiotensin II blockers, calcium&#xD;
             channel blockers, potassium sparing diuretics&#xD;
&#xD;
          -  Chronic treatment with nonsteroidal antiinflammatory drugs, antidepressants and&#xD;
             neuroleptics, lithium, cimetidine, immunosuppressive and/or antineoplastic drugs,&#xD;
             chronic systemic glucocorticoid therapy more than 7 consecutive days in one month,&#xD;
             antiarrhythmic drugs (e.g., chinidin, procainamide), anesthetics/narcotics&#xD;
&#xD;
          -  History of hypersensitivity to delapril or other ACE inhibitors, manidipine or other&#xD;
             dihydropyridine CCBs&#xD;
&#xD;
          -  Legal incapacity and/or other circumstances rendering the patient unable to understand&#xD;
             the nature, scope and possible consequences of the trial&#xD;
&#xD;
          -  Evidence of an uncooperative attitude&#xD;
&#xD;
          -  Any evidence that allows predicting that the patient will not be able to complete the&#xD;
             trial follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piero Ruggenenti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mario Negri Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASL of Ponte San Pietro - Diabetologic Unit</name>
      <address>
        <city>Ponte San Pietro</city>
        <state>Bergamo</state>
        <zip>24036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center for Rare Diseases</name>
      <address>
        <city>Ranica</city>
        <state>Bergamo</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Romano di Lombardia - Diabetologic Unit</name>
      <address>
        <city>Romano di Lombardia</city>
        <state>Bergamo</state>
        <zip>24058</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot; Bolognini &quot; - Medicine Unit</name>
      <address>
        <city>Seriate</city>
        <state>Bergamo</state>
        <zip>24068</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot; Treviglio Caravaggio&quot; - Diabetologic Unit</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas Institute - Endocrinology and Diabetologic Unit</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Ospedali Riuniti di Bergamo&quot; - Diabetologic Unit</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinolgy, Diabetes and Metabolic Disease - University Medical Center</name>
      <address>
        <city>Lubiana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Manidipine</mesh_term>
    <mesh_term>Delapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

